Title

Pancreatic Cancer: Leading to Failure of Rivaroxaban as an Anticoagulant

Division

TriStar

Hospital

Redmond

Document Type

Poster

Publication Date

10-28-2019

Keywords

vascular thromboembolism, VTE, novel oral anticoagulants, hypercoagulability, patient mortality, pancreatic cancer, medicine efficacy

Disciplines

Digestive System Diseases | Gastroenterology | Internal Medicine | Medicine and Health Sciences

Abstract

Vascular Thromboembolism (VTE) is seen with hypercoagulable state and it can be a reason of significant morbidity and mortality. Cancer is considered as one of the most common causes of hypercoagulability and developing VTE. Since novel oral anticoagulants (NOAC) have been introduced in market for VTE prophylaxis and treatment, their use have been increased significantly as they are easy to use without episodic monitoring. Rivaroxaban is one of the commonly used NOACs and some of studies have shown its good efficacy for VTE.

Publisher or Conference

American College of Gastroenterology Annual Scientific Meeting 2019

This document is currently not available here.

Share

COinS